Douglas W. Sborov, MD, MS

Articles

Overview of PERSEUS, IsKia, and GMMG-HD7

November 20th 2024

Douglas Sborov, MD, discusses a brief overview of key clinical trials, including PERSEUS, IsKia, and GMMG-HD7, highlighting their implications for the treatment of patients with NDMM.

Clinical Factors for Transplant Eligibility and Treatment Strategy in NDMM

November 20th 2024

Douglas Sborov, MD, discusses the most reported adverse events in transplant-eligible patients undergoing triplet or quadruplet therapy, as well as significant advancements on the horizon for frontline treatment in NDMM and key takeaways from recent clinical trial data that may impact clinical practice.

Current Treatment Landscape of Newly Diagnosed Multiple Myeloma Patients

November 20th 2024

Douglas Sborov, MD, discusses how key factors, such as patient eligibility for ASCT, decision-making processes for patients with transplant-eligible NDMM, and the influence of depth of response, including MRD negativity, shape frontline therapy strategies.

Dr Sborov on CAR T-Cell Therapy–Specific Long-Term Treatment Effects in Myeloma

November 11th 2024

Douglas W. Sborov, MD, MS, discusses long-term treatment outcomes for patients with myeloma who received CAR T-cell therapy vs another treatment option.

Dr Sborov on the Use of Ide-Cel and Cilta-Cel in Relapsed/Refractory Multiple Myeloma

October 30th 2024

Douglas W. Sborov, MD, MS, discusses the use of CAR T-cell therapy in patients with relapsed/refractory multiple myeloma.

Dr. Sborov on Supportive Care Approaches to Selinexor-Associated Toxicities in Multiple Myeloma

October 7th 2021

Douglas W. Sborov, MD, MS, discusses supportive care approaches for selinexor-associated toxicities in multiple myeloma.

Dr. Sborov on Managing Bispecific Antibody–Related Adverse Effects in Multiple Myeloma

September 29th 2021

Douglas W. Sborov, MD, MS, discusses management strategies for bispecific antibody–related adverse effects in multiple myeloma.

Dr. Sborov on Mitigating Monoclonal Antibody–Associated Toxicities in Multiple Myeloma

September 23rd 2021

Douglas W. Sborov, MD, MS, discusses mitigating toxicities associated with monoclonal antibodies in multiple myeloma.

Dr. Sborov on the Toxicities Associated With Novel Therapies in Multiple Myeloma

September 13th 2021

Douglas W. Sborov, MD, MS, discusses the toxicities associated with novel therapies in multiple myeloma.